Drugs / Pentoxifylline
Pentoxifylline
also known as
PTX · Trental · oxpentifylline · PTF · Pentoxifylline, generic · Pentoxiphyllin · POF · Trental SR · +1 more
Small molecule targets TLR4, TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TRENTAL | — | 1984-08-30 | fda.gov ↗ |
Trials 118 · started per year
today
US approved 1984
1
2
1
1
2
4
2
2
3
5
2
7
4
4
3
5
1
5
2
4
3
7
6
5
12
9
5
9
1
198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials · 1 missed | ||||||
| Phase 0 | NCT07086794 | Nov 2025 → Feb 2028 expected | substance-related disorder | William Stoops | Recruiting | No outcome recorded |
| Phase 0 | NCT05178953 | Aug 2021 → Jan 2022 | male infertility | Arak University of Medical Sciences | Unknown | No outcome recorded |
| Phase 0 | NCT04417049 | Jul → Nov 2021 | bipolar depression | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 0 | NCT03800433 | Oct 2019 → Apr 2020 | anemia | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT03476564 | May → Sep 2018 | female infertility | Benha University | Unknown | No outcome recorded |
| Phase 0 | NCT02953275 | Apr 2017 → Mar 2019 | Crohn disease | University of Miami | Completed | No outcome recorded |
| Phase 0 | NCT02992678 | Dec 2016 → Jun 2017 | pancreatitis | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT01292005 | Apr 2009 → Jul 2012 | acute pancreatitis | Mayo Clinic | Completed | Missed primary |
| Phase 16 trials | ||||||
| Phase 1 | NCT06087796 | Oct 2023 → Sep 2024 | alopecia areata | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT03723291 | Sep 2019 → Dec 2021 | — | University College, London | Completed | No outcome recorded |
| Phase 1 | NCT00205049 | Mar 2005 → Nov 2006 | alcoholic hepatitis | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00593658 | Jun 2004 → Oct 2006 | hepatopulmonary syndrome | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 1 | NCT00019058 | Apr 1995 → ? | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00000646 | ? → Mar 1993 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06903689 | Apr → Oct 2025 overdue | calcinosis, chronic renal failure syndrome | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06344390 | Apr → Oct 2024 | cognitive impairment with or without cerebellar ataxia | The First Hospital of Hebei Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04433988 | Nov → Dec 2022 | COVID-19 | Sadat City University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05324735 | Dec 2021 → May 2022 | major depressive disorder | Hawler Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT05271084 | Nov 2021 → Feb 2022 | major depressive disorder | Hawler Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT04094207 | Jan 2019 → Sep 2021 | schizophrenia | Sadat City University | Completed | No outcome recorded |
| Phase 1/2 | NCT00102453 | Mar 2002 → Jul 2006 | Duchenne muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | No outcome recorded |
| Phase 235 trials · 3 met primary · 6 missed | ||||||
| Phase 2 | NCT06634056 | Jun 2026 → Nov 2031 expected | non-small cell lung carcinoma, radiation pneumonitis | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT06912763 | Aug 2025 → Mar 2031 expected | head and neck cancer, lymphedema | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06944704 | Apr 2025 → Mar 2026 | hepatobiliary disorder | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT06494111 | Feb 2025 → May 2029 expected | lymphedema | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05795647 | Feb 2024 → Apr 2027 expected | osteonecrosis of the jaw | University Hospital, Limoges | Recruiting | No outcome recorded |
| Phase 2 | NCT04186559 | Feb → Nov 2024 | Behcet disease | Silk Road Therapies, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT06087237 | Oct 2023 → Jun 2024 | female breast carcinoma | Mansoura University | Completed | Met primary |
| Phase 2 | NCT05897372 | Aug 2023 → Sep 2024 | diabetic kidney disease | Iain Bressendorff | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05231980 | Jun 2022 → May 2023 | polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT03830164 | Nov 2019 → Nov 2022 | erectile dysfunction, prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03888846 | Mar → Aug 2019 | Behcet disease | Ipekyolu Ilac Ltd. Sti | Completed | No outcome recorded |
| Phase 2 | NCT03731741 | Nov 2017 → May 2018 | anemia due to chronic disorder | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT06986031 | May 2017 → Jan 2019 | male infertility | Prokrea BCN, S.L. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02397486 | May 2015 → Jun 2018 | head and neck neoplasm | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02230800 | Nov 2014 → Dec 2019 | — | Royal Marsden NHS Foundation Trust | Completed | Missed primary |
| Phase 2 | NCT01871454 | Oct 2013 → Dec 2025 | non-small cell lung carcinoma | University of Louisville | Unknown | No outcome recorded |
| Phase 2 | NCT02283710 | May 2013 → May 2014 | NAFLD1 | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01774487 | Feb 2013 → Feb 2018 | biliary atresia | Baylor College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01625845 | Jun 2012 → May 2014 | coronary artery disorder, major depressive disorder | Indiana University | Completed | Missed primary |
| Phase 2 | NCT01508221 | Jun 2011 → Feb 2017 | metastatic malignant neoplasm in the brain | University of Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT01249092 | Nov 2010 → Jun 2012 | primary biliary cholangitis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01102218 | Aug 2010 → Jan 2012 | end stage renal failure | Fresenius Medical Care North America | Terminated | Missed primary |
| Phase 2 | NCT01149304 | Jun 2009 → Nov 2017 | metastasis from malignant tumor of colon, radiation-induced disorder | University of Magdeburg | Completed | Met primary |
| Phase 2 | NCT00864916 | Mar 2009 → Dec 2012 | HIV infectious disease, atherosclerosis | Indiana University | Completed | Missed primary |
| Phase 2 | NCT00796822 | Jan 2009 → Oct 2011 | HIV infectious disease, atherosclerosis | Indiana University | Completed | Missed primary |
| Phase 2 | NCT00616382 | Mar 2008 → Mar 2010 | patent ductus arteriosus | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00590161 | Dec 2006 → Jul 2010 | metabolic dysfunction-associated steatohepatitis | Case Western Reserve University | Completed | Met primary |
| Phase 2 | NCT00271336 | Jan 2005 → Mar 2009 | necrotizing enterocolitis | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00583700 | Feb 2003 → May 2010 | breast fibrosis | University of Iowa | Completed | No outcome recorded |
| Phase 2 | NCT00188669 | Jul 2002 → ? | breast neoplasm | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 2 | NCT00188552 | Jul 2002 → ? | — | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 2 | NCT00133393 | Jan 2002 → Jul 2005 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00022204 | Jan 2000 → ? | breast cancer, lymphedema | Royal Marsden NHS Foundation Trust | Completed | Missed primary |
| Phase 2 | NCT00001877 | Feb 1999 → May 2004 | pulmonary sarcoidosis | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00001437 | Jun 1995 → Mar 2000 | radiation-induced disorder | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/311 trials · 2 missed | ||||||
| Phase 2/3 | NCT07669584 | Oct 2025 → Oct 2027 expected | azoospermia | Prokrea BCN, S.L. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05971667 | Jul → Oct 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05513560 | May 2023 → Mar 2025 | long COVID-19 | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT06040489 | Jun 2022 → Jun 2024 | mucocutaneous leishmaniasis | University of Brasilia | Unknown | No outcome recorded |
| Phase 2/3 | NCT05189535 | Oct 2021 → Sep 2023 | female breast carcinoma, peripheral neuropathy | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02951299 | May → Jun 2017 | acute kidney injury | Taipei Medical University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02451774 | Jan 2015 → Dec 2019 | childhood acute lymphoblastic leukemia | Ramón Óscar González-Ramella, Ph.D | Unknown | No outcome recorded |
| Phase 2/3 | NCT01809132 | Sep 2013 → Oct 2018 | alcoholic hepatitis | Mack Mitchell | Completed | Missed primary |
| Phase 2/3 | NCT01381055 | Mar 2012 → Jan 2015 | cutaneous leishmaniasis | Paulo Roberto Lima Machado | Completed | No outcome recorded |
| Phase 2/3 | NCT01464242 | Nov 2011 → Jan 2015 | cutaneous leishmaniasis | International Center for Training and Medical Research | Completed | No outcome recorded |
| Phase 2/3 | NCT00267670 | Mar 2005 → Sep 2009 | metabolic dysfunction-associated steatohepatitis | Northwestern University | Completed | Missed primary |
| Phase 316 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT06055257 | Jan 2025 → Dec 2027 expected | osteoradionecrosis of the mandible | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT07499817 | Oct 2023 → Apr 2026 overdue | female infertility | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 3 | NCT05284448 | Feb → Sep 2022 | metabolic dysfunction-associated steatohepatitis | Al-Azhar University | Completed | No outcome recorded |
| Phase 3 | NCT05487755 | Feb 2022 → Mar 2023 | diabetic kidney disease | Tanta University | Completed | Met primary |
| Phase 3 | NCT05284656 | Jan 2022 → Jun 2026 overdue | chronic kidney disease | Al-Azhar University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04152980 | Jan 2020 → Oct 2022 | neonatal sepsis | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04217733 | Nov 2019 → Dec 2030 expected | irritable bowel syndrome | Tanta University | Recruiting | Met primary |
| Phase 3 | NCT03040778 | Apr 2018 → May 2026 overdue | osteonecrosis of the jaw | University of Washington | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02487225 | May 2015 → Apr 2017 | acute pancreatitis, alcoholic pancreatitis, chronic pancreatitis | Mayo Clinic | Completed | Missed primary |
| Phase 3 | NCT01291433 | Mar 2011 → May 2017 | radiation-induced plexopathy | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01472263 | Sep 2009 → Sep 2012 | developmental disability, immune system disorder, tropical spastic paraparesis | Hospital Universitário Professor Edgard Santos | Completed | No outcome recorded |
| Phase 3 | NCT01455337 | Jan 2009 → Dec 2011 | alcoholic hepatitis | Inje University | Unknown | No outcome recorded |
| Phase 3 | NCT00561093 | Feb 2008 → Oct 2010 | end stage renal failure, protein-energy malnutrition | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00354198 | Aug 2006 → Aug 2009 | glomerulonephritis | National Taiwan University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00354731 | Aug 2006 → Jan 2011 | nephrotic syndrome | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00285298 | Jan 2006 → Apr 2008 | chronic kidney disease | Walter Reed Army Medical Center | Completed | Met primary |
| Phase 415 trials · 2 met primary | ||||||
| Phase 4 | NCT06265389 | Mar → Aug 2024 | — | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT05583266 | Nov 2022 → Mar 2023 | cerebrovascular disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05490953 | Jul 2022 → Dec 2023 | Hodgkins lymphoma | University of Guadalajara | Unknown | No outcome recorded |
| Phase 4 | NCT04910178 | Dec 2020 → Dec 2021 | NAFLD1, type 2 diabetes mellitus | Asmaa Abdelfattah Elsayed | Completed | No outcome recorded |
| Phase 4 | NCT03859570 | Sep 2020 → Dec 2021 | lupus nephritis | MetroHealth Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT04391231 | Jun 2020 → Jun 2022 | anemia, nonspherocytic hemolytic, heart failure | Cedars-Sinai Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT05660694 | Jan 2020 → Sep 2021 | neoplasm, oral submucous fibrosis | Altamash Institute of Dental Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03625648 | Nov 2019 → Jan 2028 expected | diabetic kidney disease | VA Office of Research and Development | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03060434 | Jun 2018 → Dec 2022 overdue | lumbar disk disease, radiculopathy | St Joseph University, Beirut, Lebanon | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02368457 | Feb 2016 | osteoradionecrosis | Hospital Vall d'Hebron | Completed | No outcome recorded |
| Phase 4 | NCT02008214 | Dec 2013 → Mar 2015 | HIV infectious disease, hepatitis C virus infection | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT02161653 | Apr 2010 → Sep 2014 | alcoholic hepatitis | Hospital General de Mexico | Completed | Met primary |
| Phase 4 | NCT01269827 | Jan 2006 → May 2008 | end stage renal failure | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00155246 | Jul 2004 → Jul 2006 | chronic kidney disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00770328 | May 2003 → May 2009 | obesity disorder | Vanderbilt University | Completed | Met primary |
| Phase not applicable20 trials · 1 missed | ||||||
| — | NCT07252518 | Oct 2025 → Jul 2026 overdue | male infertility | Mst.Sumyara Khatun | Recruiting | No outcome recorded |
| — | NCT07085806 | Jan → Jul 2025 overdue | — | Institute of Liver and Biliary Sciences, India | Recruiting | No outcome recorded |
| — | NCT07561801 | Jul 2024 → Jun 2025 | acute tubulointerstitial nephritis, chronic kidney disease | Tanta University | Completed | No outcome recorded |
| — | NCT06041932 | Nov 2023 → Aug 2024 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT07315139 | Feb → Aug 2023 | chronic kidney disease | Ain Shams University | Completed | No outcome recorded |
| — | NCT05708248 | Feb → Jul 2023 | — | Alexandria University | Unknown | No outcome recorded |
| — | NCT05502952 | Jul 2022 → Jul 2023 | alopecia areata | Sohag University | Unknown | No outcome recorded |
| — | NCT05611268 | Jun 2022 → Sep 2024 overdue | Eisenmenger syndrome | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| — | NCT05373134 | May 2022 → Apr 2023 | hepatopulmonary syndrome | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT05156684 | Jan 2022 | infertility disorder | Arak University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT04570254 | Aug → Dec 2020 | COVID-19, acute respiratory distress syndrome, viral pneumonia | Unidad Temporal COVID-19 en Centro Citibanamex | Completed | No outcome recorded |
| — | NCT03554447 | Apr 2015 → Dec 2017 | major depressive disorder | Mahmoud Samy Abdallah | Completed | No outcome recorded |
| — | NCT02592863 | Jan 2015 → Dec 2020 | peripheral vertigo | University of Missouri-Columbia | Terminated | No outcome recorded |
| — | NCT01279434 | Jan → Mar 2012 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
| — | NCT01469624 | Apr 2011 → Jun 2012 | — | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01337349 | Jul 2010 → Mar 2013 | congestive heart failure | Henry Ford Health System | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01082003 | Oct 2009 → Aug 2013 | — | Legacy Health System | Unknown | No outcome recorded |
| — | NCT00154661 | Jan 2000 → Jun 2001 | glomerulonephritis | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT00315679 | Jun 1996 → Nov 1998 | aphthous stomatitis | Manchester University NHS Foundation Trust | Completed | Missed primary |
| — | NCT00002091 | — | HIV infectious disease | Community Research Initiative of New England | Completed | No outcome recorded |
| Comparator or background therapy54 trials | ||||||
| Phase 0 | NCT05590117 Comparator | Oct 2022 → Oct 2023 | colorectal cancer, mucositis, peripheral neuropathy | Tanta University | Unknown | No outcome recorded |
| Phase 1 | NCT03836222 Comparator | Feb → Jun 2018 | — | Processa Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT06332612 Comparator | Aug → Dec 2024 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 1/2 | NCT00243789 Comparator | Sep 2005 → Dec 2007 | Duchenne muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | No outcome recorded |
| Phase 2 | NCT07349472 Comparator | Jan 2026 → Jan 2027 expected | inflammatory bowel disease | Ihab Elsayed Hassan | Recruiting | No outcome recorded |
| Phase 2 | NCT07137793 Comparator | Sep 2025 → Mar 2026 | breast cancer, doxorubicin induced cardiomyopathy | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT06998628 Comparator | Jun 2025 → May 2027 expected | rheumatoid arthritis | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06186700 Comparator | Dec 2023 → Dec 2024 | chemotherapy-induced neuropathy, female breast carcinoma | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT06176339 Comparator | Dec 2023 → Aug 2024 | female breast carcinoma | Mansoura University | Unknown | No outcome recorded |
| Phase 2 | NCT05962957 Comparator | Aug 2023 → Sep 2024 | Parkinson disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2 | NCT05575505 Comparator | Feb 2023 → May 2025 | inflammatory bowel disease | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05637086 Comparator | Dec 2022 → Dec 2026 expected | epilepsy | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2 | NCT05558761 Comparator | Oct 2022 → Apr 2024 | inflammatory bowel disease | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT03916068 Comparator | Jul 2019 → Oct 2023 | breast cancer | Legacy Health System | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03342950 Comparator | Feb 2019 → Oct 2021 | peripheral neuropathy | Terence J. Coderre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02776059 Comparator | Jan 2017 → Mar 2020 | alcoholic hepatitis | Timothy Morgan, MD | Completed | Missed primary |
| Phase 2 | NCT02530697 Background | Aug 2015 → Aug 2025 overdue | leishmaniasis | University of Brasilia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01822405 Comparator | Jul 2010 → Jul 2013 | — | Hospital Universitario de Canarias | Unknown | No outcome recorded |
| Phase 2/3 | NCT05897034 Comparator | Jun 2023 → Jun 2024 overdue | bacterial sexually transmitted disease | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05387187 Comparator | May 2022 | chronic kidney disease | Taipei Medical University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04367935 Comparator | Jan 2021 → Apr 2022 | acute coronary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT00663949 Comparator | Feb 2006 → Dec 2007 | diabetic kidney disease | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT06421870 Comparator | Mar 2024 → May 2025 | chronic kidney disease | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT06422000 Comparator | Jun 2022 → Nov 2023 | necrotizing enterocolitis | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT02898376 Background | Dec 2018 → Jul 2020 | breast carcinoma | Institut de Cancérologie de Lorraine | Unknown | No outcome recorded |
| Phase 3 | NCT03406169 Comparator | Feb 2017 → Dec 2021 | erectile dysfunction, prostate cancer | Brooke Army Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02485106 Comparator | Jul 2015 → Dec 2016 | alcoholic hepatitis | Saint Vincent's Hospital, Korea | Unknown | No outcome recorded |
| Phase 3 | NCT02163174 Comparator | May 2011 → Feb 2013 | neonatal sepsis | Abd Elazeez Attala Shabaan | Completed | No outcome recorded |
| Phase 3 | NCT01214226 Comparator | Dec 2007 → Dec 2010 | alcoholic hepatitis | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3 | NCT00162552 Comparator | Aug 2004 → Dec 2007 | cirrhosis of liver, liver failure | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00632697 Comparator | Oct 2001 → Dec 2006 | endometriosis | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 3 | NCT01263925 Comparator | Apr 2001 → Apr 2011 | intermittent vascular claudication, peripheral arterial occlusive disease 1 | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT06115174 Comparator | Nov 2023 → Nov 2024 | colorectal carcinoma | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT04977661 Comparator | Feb → May 2020 | metabolic dysfunction-associated steatohepatitis | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT03664414 Comparator | Mar 2018 → Jul 2019 | chronic kidney disease, type 2 diabetes mellitus | Maria Eugenia Galván Plata | Unknown | No outcome recorded |
| Phase 4 | NCT03006952 Comparator | Apr → Sep 2015 | diabetic kidney disease | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02971306 Background | Jul 2014 → Dec 2017 | alcoholic hepatitis | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | Met primary |
| Phase 4 | NCT01542268 Comparator | Mar 2012 → Jan 2013 | irritable bowel syndrome | Hospital Universitario de Canarias | Unknown | No outcome recorded |
| Phase 4 | NCT01382303 Comparator | Oct 2010 → Dec 2013 | type 2 diabetes mellitus | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01377285 Comparator | Jun 2010 → Dec 2018 | chronic renal failure syndrome | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01006499 Comparator | Aug 2009 → Oct 2010 | neonatal sepsis | Zekai Tahir Burak Women's Health Research and Education Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01718288 Background | Nov 2006 → Mar 2011 | peripheral arterial disease | Fadoi Foundation, Italy | Completed | No outcome recorded |
| — | NCT07626788 Comparator | Nov 2026 → Mar 2027 expected | psoriasis | Wasuchon Chaichan | Not yet recruiting | No outcome recorded |
| — | NCT07088328 Comparator | Jul 2025 → Jan 2026 overdue | brain hypoxia - ischemia | Alexandria University | Not yet recruiting | No outcome recorded |
| — | NCT06319768 Comparator | Jan → Jun 2024 | skin atrophy | Sohag University | Unknown | No outcome recorded |
| — | NCT06458465 Comparator | Oct 2023 → Sep 2024 | chronic kidney disease | Alexandria University | Completed | No outcome recorded |
| — | NCT05640817 Comparator | Jan 2023 → Jan 2026 | cisplatin toxicity | Tanta University | Completed | No outcome recorded |
| — | NCT06562998 Comparator | Jul 2022 → Apr 2024 | chemotherapy-induced neuropathy | Beni-Suef University | Completed | No outcome recorded |
| — | NCT05329116 Comparator | May → Oct 2022 | osteoarthritis, knee | Necmettin Yildiz | Unknown | No outcome recorded |
| — | NCT04739345 Comparator | Dec 2020 → Jun 2021 | COVID-19, cytokine release syndrome | Ain Shams University | Completed | No outcome recorded |
| — | NCT01676597 Background | Sep 2012 → Sep 2014 | hepatopulmonary syndrome | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT01893450 Comparator | Jun 2008 → Jun 2013 | disease of orbital part of eye adnexa | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
| — | NCT00681733 Comparator | Jan 2007 → Dec 2008 | — | Govind Ballabh Pant Hospital | Unknown | No outcome recorded |
| — | NCT01049633 Background | — | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | No longer available | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 183 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentoxifylline | “A Phase I, Single Centre, Open-Label, Non-Randomised Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental®...” NCT03836222 ↗168“23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of...” NCT03800433 ↗ “standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids” NCT01718288 ↗ “Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)” NCT03342950 ↗ “the active substance pentoxifylline has been available as tablets for decades and is used to increase peripheral blood flow in patients with circulation problems.” NCT06986031 ↗ “In this study, we investigated if pentoxifylline (PTX) and ethosuximide could potentially alleviate abdominal pain in patients with IBS treated with mebeverine.” PMID 35221706 ↗ Feb 2022 “Gel PKB171 contains pentoxifylline, which is used in assisted reproduction to treat sperm samples because of its ability to improve progressive sperm mobility” NCT07669584 ↗ “The appetite stimulating arm will include a medication known as "pentoxifylline" (also known as Trental™) and the dose will be 400 mg daily or its placebo.” NCT00561093 ↗ “Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.” NCT01082003 ↗ “Standard of care treatment will be with either prednisolone 40 mg/day for 28 days or pentoxifylline 400 mg TID for 28 days.” NCT02776059 ↗ “800 mg pentoxifylline (400 mg morning and night)” NCT06055257 ↗ |
| Known as | oxpentifylline | “Pentoxifylline (also known as oxpentifylline) is a methylxanthine derivative with strong hemorrheologic effects.” NCT06998628 ↗2“Pentoxifylline (also known as oxpentifylline)” NCT00315679 ↗ “Pentoxifylline (also known as oxpentifylline)” NCT07085806 ↗ |
| Known as | Pentoxifylline, generic | “Pentoxifylline, generic” NCT01809132 ↗ |
| Known as | Pentoxiphyllin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01279434 ↗ |
| Known as | POF | “Pentoxifylline (POF), a xanthine derivative used for many years in the treatment of peripheral vascular disease” NCT00001877 ↗ |
| Known as | PTF | “The purpose of the investigators study is to assess the impact of therapy with Pentoxifylline (PTF), a nonspecific phosphodiesterase inhibitor, on kidney function in patients...” NCT00285298 ↗2“Pentoxifylline (PTF) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and has both anti-oxidant and anti-inflammatory properties.” NCT06421870 ↗ “Pentoxifylline (PTF) appears to improve circulation through its ability to alter erythrocyte deformability and enhances capillary microcirculation.” NCT05284656 ↗ |
| Known as | PTX | “This randomized, double-blind, placebo-controlled clinical trial aimed to prospectively examine the effect of pentoxifylline (PTX) on hypoxia-inducible factor-2 alpha (HIF-2α)...” PMID 39499142 ↗ Nov 202435“We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) and/or folic acid (FA) for CKD patients to the standard care...” PMID 40826392 ↗ Aug 2025 “This study aimed to evaluate the efficacy of oral pentoxifylline (PTX), combined with standard antibiotic and supportive therapies, for treating hospitalized children with...” PMID 42086944 ↗ May 2026 “Our preliminary in vitro and in vivo research suggests that pentoxifylline (PTX) reduces vascular inflammation and improves endothelial function in HIV-infected persons not...” PMID 23593327 ↗ Apr 2013 “This study aimed to evaluate the therapeutic benefits of pentoxifylline (PTX) in treatment of adult patients with MDD as it has anti-inflammatory and phosphodiastrase...” NCT03554447 ↗ “Pentoxifylline (PTX), a methylxanthine derivative and non-selective phosphodiesterase inhibitor, has been extensively studied for its anti-inflammatory and immunomodulatory actions.” NCT07349472 ↗ “Pentoxifylline (PTX) is a methylxanthine with promising immunomodulatory properties, which can be used as an additional therapy next to antibiotics in preterm infants.” PMID 34794420 ↗ Nov 2021 “The primary aim of this study was to compare the effects of pentoxifylline (PTX) versus placebo on the histological features of nonalcoholic steatohepatitis (NASH).” PMID 21748765 ↗ Aug 2011 “Pentoxifylline (PTX) is a methylxanthine derivative that inhibits pro-inflammatory cytokines and also has shown anti-fibrotic effects in serum of patients with PBC.” NCT01249092 ↗ “Pentoxifylline (PTX), a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases (Nasiri-Toosi et al., 2013).” NCT05640817 ↗ “Pentoxifylline (PTX) has demonstrated potential in alleviating several adverse effects induced by chemotherapy in preclinical and limited clinical investigations.” PMID 41164763 ↗ Oct 2025 |
| Known as | Trental | “23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of...” NCT03800433 ↗7“The appetite stimulating arm will include a medication known as "pentoxifylline" (also known as Trental™) and the dose will be 400 mg daily or its placebo.” NCT00561093 ↗ “Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS” NCT00000646 ↗ “Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental.” NCT06115174 ↗ |
| Known as | Trental SR | “25 patients will receive pentoxifylline (Trental SR®) 400 mg three times daily with their standard therapy for 6 months.” NCT05284448 ↗ |
| Known as | trentoximal | “They will be given pentoxifylline as reno-protective drug (trentoximal, Egypharma ; E.D.A Reg.No.: 25276/2007) was administered intravenously to Neonates with perinatal hypoxia...” NCT07088328 ↗ |
| Action | Inhibit | “Pentoxifylline decreases tumor necrosis factor (TNF)” NCT00000646 ↗ |
| Modality | Small molecule | “Pentoxifylline (POF), a xanthine derivative” NCT00001877 ↗ |
| Route | Oral | “400 mg po TID” NCT00001437 ↗ |
| Target | TNF | “Pentoxifylline decreases tumor necrosis factor (TNF)” NCT00000646 ↗ |